AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced the launch of its first 2023 global call for applications to identify technological and biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel.
AION Labs’ fifth startup will focus on the development of an AI platform that identifies naturally occurring protein of interest-E3 interacting pairs that work together in specific parts of the body under specific conditions. It is also looking to model the 3D structure of the interacting complex to enable small molecule design.
AiThority: The 3 Building Blocks to Make AI Accessible
“Building on the successful launch and selection of four great startup founders for AION Labs in 2022, we are eager to tackle yet another pharmaceutical R&D challenge,” said Dr. Yair Benita, CTO of AION Labs. “We’re anticipating another strong round of applications, and look forward to working together with the chosen startup to develop a cutting-edge computational solution that will open an avenue to targeting proteins that have so far been seen as undruggable.”
AION Labs is inviting startups, computational biologists, bioinformatics and proteomics scientists, and AI and machine learning professionals to propose the development of a next-generation computational platform to identify naturally occurring protein of interest-E3 ligase interacting pairs to develop molecular glues. Original ideas that go far beyond the current state-of-the-art are being encouraged.
Read More: How ChatGPT Will Transform Customer Service
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.